AGER and metabolic dysfunction-associated steatotic liver disease: Liraglutide can inhibit the expression of RAGE [8,9], which can be activated by processed food-derived advanced glycation end products to propagate the progression of NAFLD, leading to the accumulation of liver fat, resulting in inflammation, fibrosis, insulin resistance and other fatty liver complications [10,11].